Figure 2 | British Journal of Cancer

Figure 2

From: The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

Figure 2

Mean concentration–time profiles of soluble IGF-IR after intravenous administration of figitumumab and docetaxel every 3 weeks. Concentrations of soluble IGF-IR were expressed as a percentage of individual pre-treatment baseline concentrations. Here, N indicates the number of patients with at least one measurement after the start of cycle 1 dosing.

Back to article page